Short answer
Immunovant, Inc. (IMVT) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$153M
- −27.0% YoY
- EPS (diluted)
- −$0.75
- −5.6% YoY
Source: XBRL data from the Immunovant, Inc. (IMVT) Q2 2026 10-Q on SEC EDGAR. USD.
Immunovant, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Cash and equivalents $797.8M as of June 30, 2026, expected to fund operations through potential IMVT-1402 GD launch
- Potential late-stage development expansion under evaluation following positive D2T RA Period 1 results
- Updated cash runway guidance expected after D2T RA and CLE Period 2 results later this year
- Continued net losses anticipated, with current funds insufficient for all planned development and commercialization activities
Risk Factors
- Interim or topline data risk: audit, verification, and additional patient data may materially change reported clinical results
- Clinical-trial execution risk: enrollment, site activation, CRO performance, and manufacturing constraints may delay studies
- Regulatory compliance risk: FDA or other authorities may impose clinical holds for GCP, safety, protocol, or data-integrity deficiencies
- Commercial risk: delayed trials could let competitors launch earlier and shorten exclusivity periods
- Data-integrity risk: pre-acquisition research deficiencies at licensing partners could increase development costs and delay commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Immunovant, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.